Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Aurobindo Pharma Ltd ( (IN:AUROPHARMA) ) has shared an announcement.
Aurobindo Pharma Limited announced that its subsidiary, Eugia Pharma Specialities Limited, has received final approval from the USFDA to manufacture and market Dasatinib Tablets, which are bioequivalent to Sprycel Tablets by Bristol-Myers Squibb. The product, expected to launch in Q1FY26, targets a market estimated at $1.8 billion. This approval marks the 181st ANDA approval for Eugia Pharma, enhancing its position in the oncology sector and potentially impacting stakeholders positively by expanding its product offerings in the US market.
More about Aurobindo Pharma Ltd
Aurobindo Pharma Limited is an integrated global pharmaceutical company headquartered in Hyderabad, India. It develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients globally in over 150 countries. The company has more than 30 manufacturing and packaging facilities approved by leading regulatory agencies and offers a robust product portfolio across seven major therapeutic areas.
YTD Price Performance: -11.16%
Average Trading Volume: 32,467
Current Market Cap: 697.3B INR
For a thorough assessment of AUROPHARMA stock, go to TipRanks’ Stock Analysis page.